Verve Therapeutics Inc (VERV) - Total Assets
Based on the latest financial reports, Verve Therapeutics Inc (VERV) holds total assets worth $614.16 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Verve Therapeutics Inc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Verve Therapeutics Inc - Total Assets Trend (2019–2024)
This chart illustrates how Verve Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Verve Therapeutics Inc (VERV) net assets for net asset value and shareholders' equity analysis.
Verve Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Verve Therapeutics Inc's total assets of $614.16 Million consist of 83.8% current assets and 16.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 26.7% |
| Accounts Receivable | $3.25 Million | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Verve Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see VERV market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Verve Therapeutics Inc's current assets represent 83.8% of total assets in 2024, a decrease from 88.0% in 2019.
- Cash Position: Cash and equivalents constituted 26.7% of total assets in 2024, up from 13.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Verve Therapeutics Inc Competitors by Total Assets
Key competitors of Verve Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $553.60 Million |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $260.53 Million |
Verve Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.84 | 19.82 | 10.11 |
| Quick Ratio | 9.84 | 19.82 | 10.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $459.67 Million | $589.03 Million | $66.65 Million |
Verve Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Verve Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.10 |
| Latest Market Cap to Assets Ratio | 1.54 |
| Asset Growth Rate (YoY) | -14.0% |
| Total Assets | $647.39 Million |
| Market Capitalization | $994.04 Million USD |
Valuation Analysis
Above Book Valuation: The market values Verve Therapeutics Inc's assets above their book value (1.54x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Verve Therapeutics Inc's assets decreased by 14.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Verve Therapeutics Inc (2019–2024)
The table below shows the annual total assets of Verve Therapeutics Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $647.39 Million | -13.99% |
| 2023-12-31 | $752.69 Million | +10.82% |
| 2022-12-31 | $679.22 Million | +76.82% |
| 2021-12-31 | $384.12 Million | +389.87% |
| 2020-12-31 | $78.41 Million | +262.23% |
| 2019-12-31 | $21.65 Million | -- |
About Verve Therapeutics Inc
Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company's product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hyper… Read more